Know Cancer

forgot password

An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway

Phase 1/Phase 2
18 Years
Open (Enrolling)
Histologically Confirmed Medulloblastoma, Activation of the Sonic Hedgehog (SHH) Pathway

Thank you

Trial Information

An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway

Secondary objectives are :

phase I : to collect preliminary results on the 6-month progression-free rate of the
combination vismodegib + temozolomide


To estimate in the two study arms:

- the objective response rate (Complete response + Partial Response according to WHO
criteria) after 6 months of treatment

- the duration of treatment response

- the best overall response obtained during the study

- the progression-free survival (PFS)

- the time to progression (TTP)

- the time to treatment failure (TTF) In the combination arm (vismodegib + temozolomide):
to further evaluate the safety of the combination

Inclusion Criteria:

- Age ≥ 18 years

- Patients must have histologically confirmed medulloblastoma (including posterior
fossa primitive neuroectodermal tumor) for which no known curative therapy exists

- Patients must have recurrent or refractory disease

- Patients must have evidence of measurable disease or lesion in pre-inclusion MRI.
Patients with measurable spinal disease are eligible. NB: Patients with complete
resection for recurrence are not eligible.

- Activation of the SHH pathway validated by IHC.

- ECOG performance status 0, 1 or 2 (Appendix 4).

- Life expectancy ≥ 12 weeks

- Patients must have normal organ and marrow function as defined below:

Neutrophils ≥ 1. 5 G/L Platelets ≥ 100 G /L Hemoglobin ≥ 10g/dL Creatinine clearance ≥ 50
mL/min (calculated by Cockcroft-Gault formula or MDRD formula for patients older than 65
years ) or serum creatinine within normal limits or less than 1.5 x upper limit of normal
(ULN) Total bilirubin ≤ 1.5 ULN ALAT and ASAT ≤ 2.5 ULN Serum albumin ≥ 25 g/L.

- Patients recovered from prior treatment-related toxicity (persistent treatment
related toxicity
- Prior therapy:

No prior hedgehog antagonist vismodegib or other antagonists of the hedgehog pathway, and
no prior temozolomide treatment.

More than 4 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas, 6
months after high dose therapy) or immunotherapy At least 3 months since prior
craniospinal irradiation (≥ 23 Gy) At least 8 weeks since prior local irradiation to
primary tumor At least 2 weeks since prior focal irradiation for symptomatic metastatic

At least 1 week since prior colony-stimulating factors (e.g., G-CSF, GM-CSF, or

- Women of childbearing potential* are required to have a negative serum pregnancy test
within 72 hours prior to study treatment initiation (i.e. Cycle 1 Day 1).

*: Female patients who meet at least one of the following criteria are defined as
women of non-childbearing potential:

≥50 years old and naturally amenorrheic for ≥ 1 year Permanent premature ovarian
failure confirmed by a specialist gynaecologist Previous bilateral
salpingo-oophrectomy XY genotype, Turner's syndrome, or uterine agenesis Female
patient who do not meet at least of the above criteria are defined as women of
childbearing potential.

- An embryo-fetal development study in rats has confirmed the teratogenic potential of
vismodegib. Therefore, women of child-bearing potential and men must use two forms of
effective contraception (including one barrier method- refer to Appendix 5 for
acceptable method of contraception) at least 4 weeks prior to study entry, during the
study period and for at least 7 months post-treatment. Prior to dispensing
vismodegib, the investigator must confirm and document the patient's use of two
contraceptive methods, dates of negative pregnancy test, and confirm the patient's
understanding of the teratogenic potential of vismodegib.

- Ability to understand and willingness to comply to follow-up visits.

- Covered by a medical insurance (in countries where applicable)

Exclusion Criteria:

- Tumor tissue sample not available for biological studies (from the initial diagnosis
and/or relapse)

- Pregnant or breastfeeding women are not eligible.

- History of allergic reactions attributed to compounds of similar chemical composition
to vismodegib.

- Any contraindications to temozolomide treatment as per Temodal® SPC (see Appendix 6).

- Patients with malabsorption syndrome or other condition that would interfere with
intestinal absorption. Patients must be able to swallow capsules.

- Uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, or hypokalemia, defined as
less than the lower limit of normal despite adequate electrolyte supplementation.

- History of congestive heart failure.

- History of ventricular arrhythmia requiring medication.

- Congenital long QT syndrome.

- Clinically significant unrelated systemic illness (e.g., serious infection or
significant cardiac, pulmonary, hepatic, or other organ dysfunction) that would
compromise the patient's ability to tolerate study treatment or would likely
interfere with study procedures or results.

- Patients using prohibited concomitant and/or concurrent medications (see section
"Prohibited concomitant/concurrent treatments.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To evaluate the safety of a fixed dose of vismodegib in combination with (phase I)temozolomide in adult patients with recurrent, progressive, or refractory to standard therapy medulloblastoma

Outcome Description:

number of severe toxicities occurring during the first 3 months of follow-up : Toxic death Grade 4 toxicity Any grade 3 AE leading to study treatment interruption for more than 7 days or discontinuation.

Outcome Time Frame:

during the first three months follow up

Safety Issue:


Principal Investigator

didier frappaz

Investigator Role:

Principal Investigator

Investigator Affiliation:

Centre Léon Bérard, Lyon


France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:




Start Date:

June 2012

Completion Date:

June 2016

Related Keywords:

  • Histologically Confirmed Medulloblastoma
  • Activation of the Sonic Hedgehog (SHH) Pathway
  • medulloblastoma
  • sonic hedgehog pathway
  • vismodegib
  • Medulloblastoma